AGP100

Phase 2Small molecule

AGP100 is one of 5 small molecule programs targeting Catecholaminergic Polymorphic Ventricular Tachycardia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Catecholaminergic Polymorphic Ventricular TachycardiaRecruiting

Catecholaminergic Polymorphic Ventricular TachycardiaPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Catecholaminergic Polymorphic Ventricular Tachycardia

#DrugCompanyPhaseTrials

CRD-4730

CCardurion Pharmaceuticals, Inc.

Phase 2

2 2

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 3

AGP100

AAgiana Pharmaceuticals

Phase 2

1 4

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 5

Tambocor

AAlvogen Korea

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Catecholaminergic Polymorphic Ventricular Tachycardia

NCT07263139

Clinical

Trials by Indication[1]

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Recruiting·AAgiana Pharmaceuticals·Phase 2·NCT07263139·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AGP100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGP100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGP100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Agiana Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAgiana Pharmaceuticals

AGP100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

References

Drug Info

Quick Facts

Related News